Skip to main content
Skip to content

Duplicate Document

This document appears to be a copy. The original version is:

Scientific overview of endocannabinoid system with no actionable leads
Case File
kaggle-ho-024655House Oversight

Scientific overview of endocannabinoid system with no actionable leads

Scientific overview of endocannabinoid system with no actionable leads The passage is a generic medical/scientific description of the endocannabinoid system, containing no names, transactions, dates, or allegations involving powerful actors. It offers no investigative leads. Key insights: Describes distribution of CB1/CB2 receptors in human peripheral organs.; Explains function of endocannabinoids like anandamide.; Notes presence of endocannabinoid system in animals and potential therapeutic uses.

Date
Unknown
Source
House Oversight
Reference
kaggle-ho-024655
Pages
1
Persons
1
Integrity
No Hash Available

Summary

Scientific overview of endocannabinoid system with no actionable leads The passage is a generic medical/scientific description of the endocannabinoid system, containing no names, transactions, dates, or allegations involving powerful actors. It offers no investigative leads. Key insights: Describes distribution of CB1/CB2 receptors in human peripheral organs.; Explains function of endocannabinoids like anandamide.; Notes presence of endocannabinoid system in animals and potential therapeutic uses.

Persons Referenced (1)

Tags

kagglehouse-oversightendocannabinoidcannabis-sciencemedical-research

Ask AI About This Document

0Share
PostReddit
Review This Document

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
KR L PI L AC EL CA TA CHAPTER II Cannabis Science 101 tors are located primarily in peripheral organs associated with the immune system, with the greatest concentration in the spleen, and are responsible for managing inflammation and autoimmune func- tion. Many tissues contain both CB1 and CB2 receptors, with each receptor type linked to a different physiological function. Human Endocannabinoids Endocannabinoids are the cannabinoids created naturally by the human body for delivery to CB1 and CB2 receptors. In contrast with cannabinoids introduced through cannabis consumption, endocan- nabinoids are broken down quickly by the body and cause effects with shorter durations. One well- studied endocannabinoid is anandamide (AEA). AEA is associated with the maintenance of mood, and AEA deficiency is understood to be anxiogenic (anxiety-inducing). Maintaining appropriate AEA levels within the human body is believed to reduce pain and inflammation, counter the proliferation of cancer cells, relieve anxiety and promote adult neurogenesis (a process whereby nerve cells are gener- ated from neural stem cells). Like THC, AEA has a small molecular structure that binds to CB1 recep- tors. AEA is currently being studied for its effects on angiogenesis (the process of developing new blood vessels), anxiety, cancer and memory consolidation. AEA is also present outside the human body; for example, it is a natural component of chocolate. Endocannabinoid Systems in Animals Nonhuman mammals, including dogs, cats and horses, have been shown to have endocannabinoid systems that are similar to their human counterparts: these systems employ CB1 and CB2 receptors and function through the natural production of endocannabinoids. This implies that the endocanna- binoid system is not a recent evolutionary development, but rather an ancient physiological feature of mammals in general. The cannabinoids found in cannabis, particularly CBD, have been shown to have a range of therapeutic applications for certain animals, including antibacterial and anti-inflammatory properties, appetite and bone-growth stimulation, and pain relief. The following chart depicts the canine endocannabinoid system and CB1 and CB2 receptors. Canine Endocannabinoid System ) cat B ce _ CB1 and CB2 © 2017 Ackrell Capital, LLC | Member FINRA/SIPC 19

Related Documents (6)

Dept. of JusticeOtherUnknown

EFTA Document EFTA01480194

. J.P. Morgan Entity Resolution Form J.P.Morgan D. Brokerage 3. RESOLVED, that those persons denoted above are authorized in the name and on behalf of the Entity to execute a brokerage egreement with I.P. Morgan Securities LLC and any successors or assigns, to purchase on margin or obtervise and borrow (en a secured or unsecured bass) from, sell (including short sales in a rhyme account), and lend (on a secured or unsecured basis) to, and to otherwise enter into transactors of any kind wi

1p
Dept. of JusticeAug 22, 2017

15 July 7 2016 - July 17 2016 working progress_Redacted.pdf

Kristen M. Simkins From: Sent: To: Cc: Subject: Irons, Janet < Tuesday, July 12, 2016 10:47 AM Richard C. Smith     Hello Warden Smith,     mother is anxious to hear the results of your inquiry into her daughter's health.   I'd be grateful if you could  email or call me at your earliest convenience.  I'm free today after 2 p.m.  Alternatively, we could meet after the Prison  Board of Inspectors Meeting this coming Thursday.    Best wishes,    Janet Irons    1 Kristen M. Simkins From: Sent:

1196p
Dept. of JusticeOtherUnknown

EFTA Document EFTA01456306

(j) Subject to paragraph 10(k), neither party may claim any sum by way of consequential loss or damage in the event of a failure by the other party to perform any of its obligations under this Agreement. (k) (i) Subject to subparagraph (ii) below. if as a result of a Transaction terminating before its agreed Repurchase Date under paragraphs 10(b), I0(gXiii) or 10(hXiii), the non-Defaulting Party, in the case of paragraph 10(b). Buyer. in the case of paragraph I0(gXiii). or Seller, in the

1p
Dept. of JusticeOtherUnknown

EFTA Document EFTA01367255

Amendment #4 Page 826 of 868 bible of Cement% 211 Credit risk Credit nsk is tre risk that a counter party we not meet as otegasons under a Martial instrument or customer contract eaong to a Inertial loss Tre Company is exposed to treat nsk from its operating adrvbeS (pnmanty trade receivades) and from its financing actintee, "'eluding deposes with Darin and linanCifil instnutgons Eolas sole customers ate ['wort° and Dssur. Under the bower Roches° Agreement, credit terms we 37 days. and rec

1p
House OversightUnknown

Prosecution of students for censoring Ambassador Oren cited as First Amendment enforcement

Prosecution of students for censoring Ambassador Oren cited as First Amendment enforcement The passage describes a campus free‑speech case and the author's personal involvement, but it lacks concrete leads on financial flows, wrongdoing by powerful officials, or novel allegations. No high‑ranking actors or agencies are named beyond a generic prosecutor, limiting investigative usefulness. Key insights: Students (referred to as the "Irvine Ten") were convicted for censoring a speaker.; The author was asked to testify as an expert but declined.; The author defends the prosecutor’s decision as protecting First Amendment rights.

1p
Dept. of JusticeOtherUnknown

EFTA Document EFTA01394143

GLDUS1 29 OF Enterpnses equity securities, or anyone else who otherwise qualifies as a Covered Person becomes subject to a disqualifying event. The Access Fund will be required to make representations to the Glendower GP that the Access Fund and anyone that is treated as a beneficial owner under Rule 506, has not been subject to a disqualifying event. To the extent that any of the foregoing persons is not able to make such representation, or becomes subject to a disqualifying event, the Gl

1p

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.

Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.